恒瑞医药：公司及子公司获6个药物临床试验批准将开展试验

Core Insights - The company and its subsidiaries have received approval for six drug clinical trials, which will commence shortly [1] Drug Details - SHR-4375 injection: A self-developed therapeutic biological product targeting tumor cell surface antigens, intended for advanced malignant solid tumors, entering phase Ib/II clinical research. Cumulative R&D investment is 44.88 million [6] - Adebali monoclonal antibody injection: An anti-PD-L1 monoclonal antibody that was approved for marketing in February 2023, now undergoing clinical trials for a new indication. Cumulative R&D investment is 969.8 million [6] - Bevacizumab injection: An anti-VEGF monoclonal antibody approved for marketing in June 2021, now also undergoing clinical trials for a new indication. Cumulative R&D investment is 364.73 million [6] - SHR-8068 injection: An introduced anti-CTLA-4 monoclonal antibody with a cumulative R&D investment of 262.18 million [6] - HRS-4642 injection: A self-developed KRAS G12D inhibitor in liposome formulation, with no similar drugs approved domestically or internationally. Cumulative R&D investment is 190.65 million [6] - SHR-9839 injection: A self-developed dual-target humanized antibody in subcutaneous injection form, with a cumulative R&D investment of 72.31 million [6]